Nurix Therapeutics Inc. announced the appointment of Dr. Christine Ring as the company’s general counsel, Dr. Cristiana Guiducci as vice president of immunology and oncology research and Ms. Jean Chang as vice president, clinical program management and asset strategy. In addition, Nurix announced the promotion of Dr. Gwenn Hansen, Ph.D. to senior vice president, research. Dr. Ring joins Nurix Therapeutics after holding multiple positions assisting companies to protect intellectual property, engage in licensing transactions, raise capital and transition from private to public status. Prior to joining Nurix, Dr. Ring was senior vice president, legal at Dermira Inc. Before that, she was senior vice president of technology, strategy and licensing at Amyris Inc. Dr. Guiducci has more than 15 years of industry experience focused in the area of oncology and immunology drug discovery research. Prior to joining Nurix, Dr. Guiducci was the vice president of oncology research at Dynavax Technologies where she directed all foundational research leading to the development of the Dynavax immuno-oncology assets. Prior to her work in oncology, she directed the discovery and characterization of drug candidates for autoimmune diseases at Dynavax. Ms. Chang has extensive experience in drug development and commercialization at all phases of development. Prior to joining Nurix, she was oncology project lead and vice president corporate development at Dynavax Technologies. In this role she was responsible for strategic leadership for the company’s immuno-oncology pipeline and for identifying and accessing technologies to advance its oncology programs, including establishing and managing key clinical stage collaborations with pharmaceutical partners. Ms. Chang has led marketing and new product planning for therapeutics in various disease areas including central nervous system, HIV, hepatitis B, rare diseases and autoimmune diseases and was instrumental in the successful commercial launches of Hepsera®, Ceredase®, Cerezyme® and Savella®. She previously worked at Gilead Sciences, Chiron, Cypress Bioscience, Corgentech and Anesiva, and led European marketing and global commercial operations for Genzyme.